

Commercial/Healthcare Exchange PA Criteria

Effective: November 13, 2019

Prior Authorization: Nourianz

Products Affected: Nourianz (istradefylline) oral tablets

Medication Description: Istradefylline is an adenosine A2A receptor antagonist that acts through a non-dopaminergic mechanism to improve motor function. The precise mechanism by which istradefylline exerts its therapeutic effect in Parkinson's disease is unknown.

Covered Uses: Adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. Previous therapies tried/failed

Age Restrictions: 18 years of age or older

Prescriber Restrictions: Prescribed by, or in consultation with a neurologist

Coverage Duration: 12 months

Other Criteria:

- A. Patient has a diagnosis of Parkinson's disease; **AND**
- B. Patient is experiencing "off" episodes such as muscle stiffness, slow movements, or difficulty starting movements; **AND**
- C. Patient is currently being treated with levodopa/carbidopa; **AND**
- D. Patient has previously tried two other treatments for "off" episodes including, but no limited to entacapone, rasagiline, pramipexole, ropinirole, tolcapone, cabergoline, or selegiline.

References:

1. NOURIANZ(TM) oral tablets, istradefylline oral tablets. Kyowa Kirin Inc (per FDA), Bedminster, NJ, 2019.
2. Parkinson's Foundation. Understanding Parkinson's. Available at <https://www.parkinson.org/understanding-parkinsons> Accessed on October 30, 2019.
3. National Institutes of Health. Parkinson's Disease. National Institute of Aging. Date last modified: May 16 2017. Available at: <https://www.nia.nih.gov/health/parkinsons-disease>. Accessed on October 29, 2019.
4. Mayo Clinic. Parkinson's Disease. Available at: <https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055> Accessed on October 31, 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/13/19